lonafarnib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.Īmlodipine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lofexidine, olmesartan.Įither increases effects of the other by pharmacodynamic synergism. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension. Avoid or Use Alternate Drug.Įither increases effects of the other by pharmacodynamic synergism. Olmesartan increases toxicity of lithium by decreasing renal clearance. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. Ivosidenib will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor avoid coadministration with sensitive CYP3A substrates Idelalisib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may increase risk for adverse effects of CYP3A4 substrates. Avoid or Use Alternate Drug.įexinidazole will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor increased effects and toxicities (eg, bradycardia, sinus arrest, decreased cardiac output) if amiodarone is concomitantly used with nondihydropyridine calcium channel blocker (ie, diltiazem).Įnzalutamide will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use with amlodipine and diltiazem reported an a 60% increase in amlodipine AUC. Give a low dose of calcium channel blockers initially and increase only ECG is reviewed and tolerated.ĭiltiazem will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction. Avoid or Use Alternate Drug.Ĭonivaptan will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Ĭhloroquine will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.Ĭhloramphenicol will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose according to prescribing information if needed.Įither increases toxicity of the other by pharmacodynamic synergism.
Evaluate for loss of therapeutic effect if medication must be coadministered. Avoid or substitute another drug for these medications when possible. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications.
If not feasible, avoid use of abametapir.Īpalutamide will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. Rare incidence of cardiovascular collapse and marked hyperkalemia observed when coadministered may be higher risk with nondihydropyridine calcium channel blockers.Ībametapir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor renal function periodically.Įither increases toxicity of the other by Mechanism: pharmacodynamic synergism. In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of ARBS with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Contraindicated.Ĭomment: Aliskiren use contraindicated with ARBs in patients with diabetes avoid coadministration with ARBs if GFR. Olmesartan decreases effects of aliskiren by Other (see comment).
0 kommentar(er)
